RT Journal Article
SR Electronic
T1 Deep immune profiling uncovers novel associations with clinical phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.31.22279265
DO 10.1101/2022.08.31.22279265
A1 Redmond, Christopher
A1 Kitakule, Moses M.
A1 Son, Aran
A1 Sylvester, McKella
A1 Sacco, Keith
A1 Delmonte, Ottavia
A1 Licciardi, Francesco
A1 Castagnoli, Riccardo
A1 Poli, Cecilia
A1 Espinoza, Yasmin
A1 Astudillo, Camila
A1 Weber, Sarah E.
A1 Montealegre Sanchez, Gina A.
A1 Barron, Karyl
A1 Magliocco, Mary
A1 Dobbs, Kerry
A1 Zhang, Yu
A1 Matthews, Helen
A1 Oguz, Cihan
A1 Su, Helen C.
A1 Notarangelo, Luigi D.
A1 Frischmeyer-Guerrerio, Pamela A.
A1 Schwartz, Daniella M.
YR 2022
UL http://medrxiv.org/content/early/2022/09/02/2022.08.31.22279265.abstract
AB Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable and include fever, gastrointestinal (GI) disease, shock, and Kawasaki Disease-like illness (MIS-C/KD). Compared to patients with acute COVID, patients with MIS-C have a distinct immune signature and expansion of TRVB11 expressing T cells. However, the relationship between immunological and clinical phenotypes of MIS-C is unknown. Here, we measured serum biomarkers, TCR repertoire, and SARS-CoV2-specific T cell responses in a cohort of 76 MIS-C patients. Serum biomarkers associated with macrophage and Th1 activation were elevated in patients with shock, consistent with previous reports. Significantly increased SARS-CoV-2-induced IFN-γ, IL-2, and TNF-α production were seen in CD4+ T cells from patients with neurologic involvement and respiratory failure. Diarrhea was associated with a significant reduction in shock-associated serum biomarkers, suggesting a protective effect. TRVB11 usage was highly associated with MIS-C/KD and coronary aneurysms, suggesting a potential biomarker for these manifestations in MIS-C patients. By identifying novel immunologic associations with the different clinical phenotypes of MIS-C, this study provides insights into the clinical heterogeneity of MIS-C. These unique immunophenotypic associations could provide biomarkers to identify patients at risk for severe complications of MIS-C, including shock and MIS-C/KD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the intramural research programs of NIAID and NIAMS, National Institutes of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was a natural history study of patients with MIS-C enrolled at the referring institutions. Informed consent was provided by the parents or guardians and/or assent by minors. Sample size was not predetermined. Blood samples were collected between Mar 2020 and Feb 2021 under protocols approved by the following institutional review boards (IRBs): (1)Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile (protocol 2020-41) (2)Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (protocol 20200037677) (3)Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino, Turin, Italy (protocol 00282/2020) (4)Ethics Committee of the University of Naples Federico II, Naples, Italy (protocol 158/20); Comitato Etico Provinciale, Brescia, Italy (protocol NP-4000) (5)University of Milano Bicocca-San Gerardo Hospital, Monza, and Ethics Committee of the National Institute of Infectious Diseases Lazzaro Spallanzani, Italy (protocol 84/2020) (6)Hadassah Medical Organization IRB, Jerusalem, Israel (protocol HMO-235-20) (7)National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA (protocols NCT04582903, NCT03394053 and NCT03610802) All identifiers included in this study are study identifiers that cannot reveal the identity of the research subjects and are publicly available through other works published by the NIAID COVID consortium.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors